ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
In a bid to bolster its oncology pipeline, Gilead Sciences will pay $510 million to acquire Ontario-based YM BioSciences. The centerpiece of the deal is CYT387, an aminopyrimidine derivative that blocks JAK1 and JAK2, two enzymes implicated in rare blood cancers called myeloproliferative neoplasms. YM recently unveiled promising data from a Phase I/II study of CYT387 to treat myelofibrosis, a chronic bone marrow disorder. Gilead says it will launch a Phase III study of the compound in the second half of 2013. If approved, CYT387 will compete with Incyte’s Jakafi, a JAK inhibitor that won FDA approval in November 2011. The YM deal marks the second major oncology acquisition for Gilead. In early 2011, it bought Seattle-based Calistoga Pharmaceuticals for up to $600 million. That purchase brought CAL-101, a PI3K-δ inhibitor currently in Phase III trials to treat chronic lymphocytic leukemia.
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on X